ALK and non-small cell lung carcinoma: Increasing evidences have indicated that ALK inhibitors in combination with HDACIs could synergistically induce the anti-proliferative effects on ALK inhibitor resistant cells or xenografts and are more efficient in ALK positive NSCLC patients.19–22